At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 123 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis
In Brief
A Phase 4 clinical trial evaluating Apremilast for Psoriatic Arthritis. Completed, enrolled 123 participants across 36 sites in 11 countries.
Detailed Summary
This study is designed to assess the efficacy of apremilast, either in monotherapy or with stable methotrexate, on imaging outcomes in adults with active psoriatic arthritis with less than 5 years of disease duration (since diagnosis), and who are naïve to biologic therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustria, Belgium, Canada, Denmark, Germany, Italy, Russia, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartFeb 2019
Primary CompletionOct 2021
Study CompletionMay 2022
TodayJul 2026
First PostedDec 20, 2018
Enrollment StartFeb 6, 2019
Primary CompletionOct 26, 2021
Study CompletionMay 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.5 years ago
Interventions
Apremilastdrug
Tablets for oral administration